Pseudohypoaldosteronism type II: The Relevance of A Challenging Diagnosis

II型假性醛固酮增多症:一项具有挑战性的诊断的意义

阅读:1

Abstract

Pseudohypoaldosteronism type II (PHA II) is a rare genetic syndrome caused by mutations in the WNK1, WNK4, KLHL3 and CUL3 genes, leading to hypertension, hyperkalaemia, and hyperchloremic metabolic acidosis. Each mutation confers a different phenotype, with a large spectrum of clinical presentations, which can delay the diagnosis. We report a case of a 31-year-old female with hypertension. She had uncharacteristic facies, average height and no family history of hypertension or hyperkalaemia. Laboratory data showed hyperkalaemia, hyperchloremic metabolic acidosis, hypercalciuria and suppressed renin. Genetic testing revealed a c.478G>T, p.(Asp160Tyr) variant in the KLHL3 gene, in apparent homozygosity. Based on clinical history, laboratory findings, and genetic testing, a diagnosis of PHA II was made. This is a representative case of a mild PHA II phenotype, with a non-previously reported KLHL3 mutation, highlighting the importance of a high level of suspicion for PHA II. LEARNING POINTS: We report a case of a young woman with PHA II caused by a novel variant in KLHL3, that highlights the importance of a high level of clinical suspicion for PHA II diagnosis in patients with milder phenotypes and without family history.PHA II should be considered in all patients with low-renin hypertension, hyperkalaemia, hyperchloremic metabolic acidosis and hypercalciuria, regardless of age, clinical features, or family history.Early diagnosis is extremely important because PHA II can be effectively treated with low dose thiazides, avoiding end organ damage onset.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。